Eswatini vs Guinea-Bissau: Statin use vs. average non-HDL cholesterol levels
Eswatini
2.8
in 2018
Guinea-Bissau
2.8
in 2018
Eswatini rank
163rd
Guinea-Bissau rank
163rd
Statin use vs. average non-HDL cholesterol levels over time
- Eswatini
- Guinea-Bissau
How they compare
Eswatini currently reports 2.8 against 2.8 in Guinea-Bissau, a difference of 0.
The two have swapped places 3 times across 39 shared years of data; in 1980 it was Eswatini ahead.
Eswatini ranks 163rd and Guinea-Bissau ranks 163rd of 191 countries.
Across the 4 decades both report, Eswatini averaged higher in 1 and Guinea-Bissau in 3.
Head to head by decade
| Decade | Eswatini | Guinea-Bissau | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.46 | 2.41 | 0.05 | Eswatini |
| 1990s | 2.58 | 2.59 | 0.01 | Guinea-Bissau |
| 2000s | 2.69 | 2.7 | 0.01 | Guinea-Bissau |
| 2010s | 2.77 | 2.8 | 0.0333 | Guinea-Bissau |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Eswatini or Guinea-Bissau?
- Eswatini, at 2.8 against 2.8 in Guinea-Bissau as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Eswatini and Guinea-Bissau?
- 0, with Eswatini ahead.
- How many years of comparable data are there for Eswatini and Guinea-Bissau?
- 39 years are reported by both, from 1980 to 2018.
- How do Eswatini and Guinea-Bissau rank globally for statin use vs. average non-hdl cholesterol levels?
- Eswatini ranks 163rd and Guinea-Bissau ranks 163rd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.